Silvia Busquets Rius

List of Publications by Year
in descending order

156 papers	8,512 citations	30070 54 h-index	51608 86 g-index
159 all docs	159 docs citations	159 times ranked	8151 citing authors

#	Article	IF	Citations
1	Cancer cachexia: understanding the molecular basis. Nature Reviews Cancer, 2014, 14, 754-762.	28.4	991
2	Effects of Water Stress on Respiration in Soybean Leaves. Plant Physiology, 2005, 139, 466-473.	4.8	245
3	Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology, 2015, 22, 100-106.	3.5	231
4	Inter-tissue communication in cancer cachexia. Nature Reviews Endocrinology, 2019, 15, 9-20.	9.6	191
5	Cross-talk between skeletal muscle and adipose tissue: A link with obesity?. Medicinal Research Reviews, 2005, 25, 49-65.	10.5	162
6	The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2009, 3, 263-268.	1.3	162
7	Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. British Journal of Cancer, 2000, 83, 526-531.	6.4	160
8	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	1.8	149
9	Anticachectic Effects of Formoterol. Cancer Research, 2004, 64, 6725-6731.	0.9	148
10	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 17-24.	2.4	146
11	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. International Journal of Biochemistry and Cell Biology, 2005, 37, 1084-1104.	2.8	144
12	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 87-93.	7.3	138
13	Journey from cachexia to obesity by TNF. FASEB Journal, 1997, 11, 743-751.	0.5	123
14	Increased muscle ubiquitin mRNA levels in gastric cancer patients. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R1518-R1523.	1.8	123
15	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 37-43.	7.3	115
16	Cytokines in the pathogenesis of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	114
17	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2005, 579, 1646-1652.	2.8	109
18	Myostatin: more than just a regulator of muscle mass. Drug Discovery Today, 2012, 17, 702-709.	6.4	105

#	Article	IF	Citations
19	Cancer cachexia: the molecular mechanisms. International Journal of Biochemistry and Cell Biology, 2003, 35, 405-409.	2.8	102
20	Are there any benefits of exercise training in cancer cachexia?. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 73-76.	7.3	102
21	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Letters, 1998, 133, 83-87.	7.2	98
22	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Letters, 2004, 569, 201-206.	2.8	95
23	DNA Fragmentation Occurs in Skeletal Muscle during Tumor Growth: A Link with Cancer Cachexia?. Biochemical and Biophysical Research Communications, 2000, 270, 533-537.	2.1	94
24	The role of uncoupling proteins in pathophysiological states. Biochemical and Biophysical Research Communications, 2002, 293, 1145-1152.	2.1	90
25	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 2036-2046.	2.8	89
26	In the rat, tumor necrosis factor Î± administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Letters, 1998, 440, 348-350.	2.8	88
27	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Letters, 2001, 167, 33-38.	7.2	88
28	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochimica Et Biophysica Acta - General Subjects, 2002, 1570, 33-37.	2.4	87
29	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition, 2005, 21, 977-985.	2.4	86
30	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2770-2778.	2.4	83
31	Effects of Eicosapentaenoic Acid (EPA) Treatment on Insulin Sensitivity in an Animal Model of Diabetes: Improvement of the Inflammatory Status. Obesity, 2011, 19, 362-369.	3.0	80
32	Interleukin-15 increases glucose uptake in skeletal muscle An antidiabetogenic effect of the cytokine. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 1613-1617.	2.4	79
33	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. International Journal of Oncology, 2013, 43, 886-894.	3.3	79
34	Central Melanin-Concentrating Hormone Influences Liver and Adipose Metabolism Via Specific Hypothalamic Nuclei and Efferent Autonomic/JNK1 Pathways. Gastroenterology, 2013, 144, 636-649.e6.	1.3	79
35	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. Oncotarget, 2015, 6, 43202-43215.	1.8	78
36	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 95-104.	7.3	72

#	Article	IF	Citations
37	Cachexia: a problem of energetic inefficiency. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 279-286.	7.3	72
38	TNF-Î± is involved in activating DNA fragmentation in skeletal muscle. British Journal of Cancer, 2002, 86, 1012-1016.	6.4	71
39	Redox Balance and Carbonylated Proteins in Limb and Heart Muscles of Cachectic Rats. Antioxidants and Redox Signaling, 2010, 12, 365-380.	5.4	71
40	Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. International Journal of Molecular Medicine, 2011, 27, 15-24.	4.0	70
41	Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. Journal of Molecular Biology, 2019, 431, 2674-2686.	4.2	69
42	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters, 2007, 245, 144-148.	7.2	68
43	Impact on fatty acid metabolism and differential localization of FATP1 and FAT/CD36 proteins delivered in cultured human muscle cells. American Journal of Physiology - Cell Physiology, 2005, 288, C1264-C1272.	4.6	67
44	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Letters, 1998, 436, 415-418.	2.8	64
45	Anti-inflammatory therapies in cancer cachexia. European Journal of Pharmacology, 2011, 668, S81-S86.	3.5	63
46	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discovery Today, 2009, 14, 208-213.	6.4	61
47	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. Journal of Cellular Physiology, 2000, 184, 380-384.	4.1	60
48	Novel approaches to the treatment of cachexia. Drug Discovery Today, 2008, 13, 73-78.	6.4	60
49	Counteracting Inflammation: A Promising Therapy in Cachexia. Critical Reviews in Oncogenesis, 2012, 17, 253-262.	0.4	59
50	Changes in Mitochondrial Electron Partitioning in Response to Herbicides Inhibiting Branched-Chain Amino Acid Biosynthesis in Soybean. Plant Physiology, 2003, 133, 1351-1359.	4.8	58
51	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clinical Nutrition, 2007, 26, 614-618.	5.0	58
52	Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. Seminars in Cell and Developmental Biology, 2016, 54, 20-27.	5.0	58
53	Optimal management of cancer anorexia–cachexia syndrome. Cancer Management and Research, 2010, 2, 27.	1.9	57
54	Muscle wasting in cancer. Current Opinion in Clinical Nutrition and Metabolic Care, 2015, 18, 221-225.	2.5	56

#	Article	IF	Citations
55	Tumor necrosis factor-Î± exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2002, 1542, 66-72.	4.1	55
56	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <scp>II</scp> receptor inhibition and Î²â€2 agonist. International Journal of Cancer, 2016, 138, 2021-2029.	5.1	55
57	Novel targeted therapies for cancer cachexia. Biochemical Journal, 2017, 474, 2663-2678.	3.7	55
58	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. International Journal of Molecular Medicine, 2005, 16, 471-6.	4.0	54
59	Effects of interleukin-15 on lipid oxidation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 37-42.	2.4	50
60	Cytokines as Mediators and Targets for Cancer Cachexia. Cancer Treatment and Research, 2006, 130, 199-217.	0.5	50
61	Mediators of cachexia in cancer patients. Nutrition, 2019, 66, 11-15.	2.4	50
62	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. FEBS Letters, 2005, 579, 717-722.	2.8	48
63	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. Frontiers in Physiology, 2017, 8, 92.	2.8	46
64	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 48-59.	7.3	45
65	The Increased Skeletal Muscle Protein Turnover of the Streptozotozin Diabetic Rat Is Associated with High Concentrations of Branched-Chain Amino Acids. Biochemical and Molecular Medicine, 1997, 61, 87-94.	1.4	44
66	Mechanisms and treatment of cancer cachexia. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, S19-S24.	2.6	44
67	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 315-320.	7.3	44
68	Therapeutic strategies against cancer cachexia. European Journal of Translational Myology, 2019, 29, 7960.	1.7	44
69	Catabolic mediators as targets for cancer cachexia. Drug Discovery Today, 2003, 8, 838-844.	6.4	43
70	Are Peroxisome Proliferator-Activated Receptors Involved in Skeletal Muscle Wasting during Experimental Cancer Cachexia? Role of Î²2-Adrenergic Agonists. Cancer Research, 2007, 67, 6512-6519.	0.9	43
71	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. International Journal of Biochemistry and Cell Biology, 2008, 40, 1674-1678.	2.8	43
72	Nonmuscle Tissues Contribution to Cancer Cachexia. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	43

#	Article	IF	Citations
73	Mechanisms to explain wasting of muscle and fat in cancer cachexia. Current Opinion in Supportive and Palliative Care, 2007, 1, 293-298.	1.3	42
74	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clinical Nutrition, 2007, 26, 239-244.	5.0	42
75	The Pharmacological Treatment of Cachexia. Current Drug Targets, 2004, 5, 265-277.	2.1	41
76	Effects of ILâ€15 on Rat Brown Adipose Tissue: Uncoupling Proteins and PPARs. Obesity, 2008, 16, 285-289.	3.0	40
77	Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. Biochimie, 2018, 149, 79-91.	2.6	39
78	Branched-chain amino acids: A role in skeletal muscle proteolysis in catabolic states?. Journal of Cellular Physiology, 2002, 191, 283-289.	4.1	38
79	The pivotal role of cytokines in muscle wasting during cancer. International Journal of Biochemistry and Cell Biology, 2005, 37, 1609-1619.	2.8	38
80	Differences in food intake of tumourâ€bearing cachectic mice are associated with hypothalamic serotonin signalling. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 84-94.	7.3	38
81	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine, 2003, 22, 1-4.	3.2	37
82	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clinical Nutrition, 2012, 31, 889-895.	5.0	37
83	TNF-Î± modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Letters, 2002, 175, 181-185.	7.2	33
84	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. FEBS Letters, 2009, 583, 350-356.	2.8	33
85	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncology Reports, 2011, 25, 189-93.	2.6	33
86	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. Journal of Nutritional Biochemistry, 2000, 11, 431-435.	4.2	31
87	Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochimica Et Biophysica Acta - General Subjects, 2000, 1475, 5-9.	2.4	31
88	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. Oncology Letters, 2012, 3, 185-189.	1.8	31
89	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. FEBS Letters, 2001, 505, 255-258.	2.8	29
90	Antiproteolytic effects of plasma from hibernating bears: A new approach for muscle wasting therapy?. Clinical Nutrition, 2007, 26, 658-661.	5.0	29

#	Article	IF	Citations
91	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. Clinical Nutrition, 2010, 29, 733-737.	5.0	27
92	The systemic inflammatory response is involved in the regulation of K+channel expression in brain via TNF-Î±-dependent and -independent pathways. FEBS Letters, 2004, 572, 189-194.	2.8	26
93	The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. FEBS Letters, 2006, 580, 691-696.	2.8	26
94	Interleukinâ€15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. Lipids, 2011, 46, 1033-1042.	1.7	25
95	Interleukin-15 decreases proteolysis in skeletal muscle: A direct effect. International Journal of Molecular Medicine, 2005, 16, 471.	4.0	24
96	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. PLoS ONE, 2014, 9, e113931.	2.5	24
97	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-Î±?. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1499, 249-256.	4.1	23
98	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: Possible involvement on in vivo adipocyte differentiation. International Journal of Molecular Medicine, 2009, 24, 453-8.	4.0	23
99	Sirtuin 1 in skeletal muscle of cachectic tumourâ€bearing rats: a role in impaired regeneration?. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 57-62.	7.3	22
100	Metabolic interrelationships between liver and skeletal muscle in pathological states. Life Sciences, 2001, 69, 1345-1361.	4.3	21
101	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle and Nerve, 2008, 37, 190-195.	2.2	21
102	Impaired voltage-gated K+channel expression in brain during experimental cancer cachexia. FEBS Letters, 2003, 536, 45-50.	2.8	20
103	Title is missing!. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 401-406.	2.5	20
104	A differential pattern of gene expression in skeletal muscle of tumorâ€bearing rats reveals dysregulation of excitationâ€"contraction coupling together with additional muscle alterations. Muscle and Nerve, 2014, 49, 233-248.	2.2	20
105	Exercise Reduces the Resumption of Tumor Growth and Proteolytic Pathways in the Skeletal Muscle of Mice Following Chemotherapy. Cancers, 2020, 12, 3466.	3.7	20
106	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. PeerJ, 2017, 5, e4109.	2.0	20
107	Targets in clinical oncology: the metabolic environment of the patient. Frontiers in Bioscience - Landmark, 2007, 12, 3024.	3.0	18
108	Theophylline is able to partially revert cachexia in tumour-bearing rats. Nutrition and Metabolism, 2012, 9, 76.	3.0	18

#	Article	IF	Citations
109	Cancer cachexia, a clinical challenge. Current Opinion in Oncology, 2019, 31, 286-290.	2.4	18
110	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. Cancer Letters, 2003, 200, 153-160.	7.2	17
111	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. Journal of Lipid Research, 2013, 54, 3045-3051.	4.2	17
112	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. Frontiers in Physiology, 2017, 8, 184.	2.8	17
113	Mechanism for the increased skeletal muscle protein degradation in the obese zucker rat. Journal of Nutritional Biochemistry, 1999, 10, 244-248.	4.2	16
114	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: A role in muscle wasting?. Biochimica Et Biophysica Acta - General Subjects, 2006, 1760, 253-258.	2.4	16
115	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. Experimental and Therapeutic Medicine, 2011, 2, 731-735.	1.8	16
116	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia. , 2011, , 9-35.		16
117	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 2007, 30, 1239-45.	3.3	15
118	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817-9.	4.0	13
119	The AP-1/NF-îºB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. International Journal of Oncology, 0, , .	3.3	12
120	Sepsis induces DNA fragmentation in rat skeletal muscle. European Cytokine Network, 2003, 14, 256-9.	2.0	12
121	Muscle ubiquitin m-rNA levels in patients with end-stage renal disease on maintenance hemodialysis. Journal of Nephrology, 2002, 15, 552-7.	2.0	11
122	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. Clinical Nutrition, 2011, 30, 33-37.	5.0	10
123	Differential structural features in soleus and gastrocnemius of carnitineâ€treated cancer cachectic rats. Journal of Cellular Physiology, 2020, 235, 526-537.	4.1	10
124	Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy. Biochimica Et Biophysica Acta - General Subjects, 2007, 1770, 1028-1036.	2.4	9
125	The animal cachexia score (ACASCO). Animal Models and Experimental Medicine, 2019, 2, 201-209.	3.3	9
126	Formoterol May Activate Rat Muscle Regeneration During Cancer Cachexia. Insciences Journal, 0, , 1-17.	0.7	9

#	Article	IF	Citations
127	Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. Anticancer Research, 2009, 29, 1315-7.	1.1	9
128	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963-7.	4.0	8
129	Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs, 2007, 12, 555-570.	2.4	7
130	BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. Oncology Reports, 2006, 15, 1425-8.	2.6	6
131	The Role of Cytokines in Cancer Cachexia. , 2006, , 467-475.		5
132	Patterns of gene expression in muscle and fat in tumorâ€bearing rats: Effects of CRF2R agonist on cachexia. Muscle and Nerve, 2010, 42, 936-949.	2.2	5
133	Effects of formoterol on protein metabolism in myotubes during hyperthermia. Muscle and Nerve, 2011, 43, 268-273.	2.2	5
134	Omegaâ€3 and omegaâ€3/curcuminâ€enriched fruit juices decrease tumour growth and reduce muscle wasting in tumourâ€bearing mice. JCSM Rapid Communications, 2018, 1, 1-10.	1.6	5
135	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma. International Journal of Molecular Medicine, 2004, 14, 719-23.	4.0	5
136	Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice. Oncology Reports, 2008, 19, 253-6.	2.6	5
137	PPARdelta mediates IL15 metabolic actions in myotubes: effects of hyperthermia. International Journal of Molecular Medicine, 2009, 24, 63-8.	4.0	5
138	Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Letters, 2000, 157, 99-103.	7.2	4
139	Rat liver lipogenesis is modulated by interleukin-15. International Journal of Molecular Medicine, 2004, 13, 817.	4.0	4
140	Effects of the PPARÎ³ agonist GW1929 on muscle wasting in tumour-bearing mice. Oncology Reports, 0, , .	2.6	4
141	Win 55,212-2, atenolol and subdiaphragmatic vagotomy prevent acceleration of gastric emptying induced by cachexia via Yoshida-AH-130Âcells in rats. European Journal of Pharmacology, 2020, 877, 173087.	3.5	4
142	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. E-SPEN Journal, 2012, 7, e135-e138.	0.5	3
143	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. JCSM Rapid Communications, 2018, 1, 1-15.	1.6	3
144	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. International Journal of Molecular Medicine, 2004, 14, 719.	4.0	2

#	Article	IF	Citations
145	Interleukin-15 decreases lipid intestinal absorption. International Journal of Molecular Medicine, 2005, 15, 963.	4.0	2
146	BARD1 content correlates with increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. Oncology Reports, 2006, 15, 1425.	2.6	2
147	Editorial: Biological Mechanism-Based and Patient-Centered Management of Cancer-Related Symptoms and Syndromes. Frontiers in Physiology, 2018, 9, 1819.	2.8	2
148	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. ChemInform, 2005, 36, no.	0.0	1
149	PPARÎ´ mediates IL15 metabolic actions in myotubes: Effects of hyperthermia. International Journal of Molecular Medicine, 2009, 24, .	4.0	1
150	Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats. Biochemistry and Biophysics Reports, 2018, 14, 26-34.	1.3	1
151	Lack of Synergy Between Î²-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. OncoTargets and Therapy, 2021, Volume 14, 1953-1959.	2.0	1
152	Recent Developments in Treatment of Cachexia. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 259-273.	0.6	1
153	Therapeutic strategies in cachexia: Current and future directions. Drugs of the Future, 2010, 35, 41.	0.1	1
154	Chediak-Steinbrinck-Higashi Syndrome. , 2009, , 314-314.		0
155	Nutrition and cachexia. , 2012, , 185-194.		0
156	The cachexia score (CASCO) as a tool for staging cachectic cancer patients.. Journal of Clinical Oncology, 2014, 32, e20700-e20700.	1.6	0